Erlotinib-induced trichomegaly in a male patient with pancreatic cancer.

In this report we present a case of erlotinib-induced trichomegaly in a male patient who received erlotinib for his pancreatic cancer. Trichomegaly as a side effect of epidermal growth factor receptor (EGFR) inhibitor therapy is uncommon in male patients. Also, it has not been reported previously in a patient with pancreatic cancer. Previous reported cases all involved female lung cancer patients. We emphasize the importance of recognizing the side effects of EGFR inhibitor therapy and its implications on the prognosis of the cancer treated.